To Be Discontinued Injection Gastroenterology
Mirikizumab-mrkz Injection · 263 days since initial FDA posting
Brand: OMVOH
FDA lists Mirikizumab-mrkz Injection as To Be Discontinued (Eli Lilly and Co.).
No availability text on this FDA row.
Mirikizumab-mrkz Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Mirikizumab-mrkz Injection
- Manufacturer
- Eli Lilly and Co.
- Dosage Form
- Injection
- Presentation
- Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)
- Package NDC
- 0002-8870-27
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Dec 22, 2025
- Last Updated
- Dec 22, 2025
- Therapeutic Category
- Gastroenterology, Other
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
Nearby, Other Mirikizumab-mrkz Shortage Records
FDA reason on file: A business decision was made to discontinue. General shortage guidance lives on the tracker hub.